Please login to the form below

Not currently logged in
Email:
Password:

head and neck cancer

This page shows the latest head and neck cancer news and features for those working in and with pharma, biotech and healthcare.

AZ’s MYSTIC survival data is in – and it’s a bust

AZ’s MYSTIC survival data is in – and it’s a bust

Imfinzi failed to achieve OS improvement. AstraZeneca has released the overall survival (OS) data from its MYSTIC trial of Imfinzi and tremelimumab in advanced non-small cell lung cancer (NSCLC), and ... In the meantime, AZ also has trials of Imfinzi

Latest news

  • Roche builds on Immunocore ImmTAC deal Roche builds on Immunocore ImmTAC deal

    The trial is scheduled to start in early 2019, and will include a host of cancers, including non-small cell lung cancer (NSCLC), bladder cancer, head and neck cancer, gastric cancer ... Those molecules are based on soluble, engineered TCR’s, which

  • Soon-Shiong presents first data on cancer memory vaccine at SITC Soon-Shiong presents first data on cancer memory vaccine at SITC

    NK) cells, tumour antigens and drugs achieved tumour responses in heavily pre-treated patients with advanced cases of triple-negative breast cancer, head and neck cancer, and pancreatic cancer. ... The cocktail achieved disease control in four out of

  • AZ swells immuno-oncology pipeline with Innate deal AZ swells immuno-oncology pipeline with Innate deal

    two primary endpoints in the MYSTIC trial of Imfinzi plus AZ’s experimental CTLA4 inhibitor tremelimumab in first-line lung cancer treatment. ... The AZ deal is a boost for Innate after it was forced to abandon BMS-partnered checkpoint inhibitor

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    Merck &Co/MSD – already dominating non-small cell lung cancer with Keytruda (pembrolizumab) – will have overall survival data for its drug in first-line squamous head and neck cancer from the ... 8040 in pancreatic cancer and a phase 1 study of the

  • Imfinzi aces survival challenge in lung cancer Imfinzi aces survival challenge in lung cancer

    The new data in locally-advanced, non-small cell lung cancer (NSCLC) patients whose tumours cannot be removed surgically is a first for an immuno-oncology drug and could quickly accelerate ... second-line head and neck cancer, small cell lung cancer (SCLC

More from news
Approximately 6 fully matching, plus 101 partially matching documents found.

Latest Intelligence

  • Immunisation politicised Immunisation politicised

    sexually transmitted human papilloma virus (HPV), including strains that lead to cervical cancer. ... For example, the remarkable silence around the fact that some strains of HPV can also cause penile cancer, anal cancer, and cancer of the head and neck

  • Pharma deals in August 2015 Pharma deals in August 2015

    virus. INO-3112 generates killer T-cell responses to HPV 16 and 18 driven tumours and is in phase I / II clinical studies for cervical and head and neck cancers. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐ 3112 vaccine in P1/2 for

  • Lonafarnib: promising results in first-ever trial for progeria Lonafarnib: promising results in first-ever trial for progeria

    Lonafarnib and tipifarnib are the most successful of the FTIs, currently in Phase II development for breast cancer, and acute myeloid leukaemia and glioma, respectively. ... Development in other oncological indications (chronic myeloid leukaemia,

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Prior to this, he was director of clinical oncology at Bristol-Myers Squibb where he worked on the clinical development of Erbitux (cetuximab), which is approved for colorectal cancer and head ... and neck cancer.

  • VentiRx appoints James Kyle Bryan as chief medical officer VentiRx appoints James Kyle Bryan as chief medical officer

    During his career, Dr Bryan has focused on drug discovery in oncology, and has a medical background in haematology and oncology. ... This experience will benefit VentiRx as it prepares to advance the development of VTX-2337 for patients with ovarian

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... Rubbing salt into BMS’ s wounds, Merck's  Keytruda snagged

  • ASCO 2015: What you missed in Chicago

    Specifically, we thought the checkpoint inhibitors in head and neck, lung cancer and melanoma really shone. ... Patel SP et al Mol Cancer Ther 2015[2] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics